GSK vs RTX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jan 31, 2026

GSK

60.8
AI Score
VS
RTX Wins

RTX

64.0
AI Score

Investment Advisor Scores

GSK

61score
Recommendation
BUY

RTX

64score
Recommendation
BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric GSK RTX Winner
Forward P/E 9.6432 30.303 GSK
PEG Ratio 0.4287 1.7496 GSK
Revenue Growth 6.7% 12.1% RTX
Earnings Growth 23.2% 8.3% GSK
Tradestie Score 60.8/100 64.0/100 RTX
Profit Margin 17.1% 7.6% GSK
Beta 1.00 1.00 Tie
AI Recommendation BUY BUY Tie

Frequently Asked Questions

Based on our detailed analysis, RTX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.